Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Compensatory changes in degenerating spinal motoneurons sustain functional sparing in the SOD1-G93A mouse model of amyotrophic lateral sclerosis.

Giusto E, Codrich M, de Leo G, Francardo V, Coradazzi M, Parenti R, Gulisano M, Vicario N, Gulino R, Leanza G.

J Comp Neurol. 2019 Jul 31. doi: 10.1002/cne.24751. [Epub ahead of print]

PMID:
31364764
2.

Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson's Disease.

Francardo V, Geva M, Bez F, Denis Q, Steiner L, Hayden MR, Cenci MA.

Neurotherapeutics. 2019 Apr;16(2):465-479. doi: 10.1007/s13311-018-00699-9.

3.

Animal models of L-DOPA-induced dyskinesia: the 6-OHDA-lesioned rat and mouse.

Tronci E, Francardo V.

J Neural Transm (Vienna). 2018 Aug;125(8):1137-1144. doi: 10.1007/s00702-017-1825-5. Epub 2017 Dec 14. Review.

PMID:
29242978
4.

Modeling Parkinson's disease and treatment complications in rodents: Potentials and pitfalls of the current options.

Francardo V.

Behav Brain Res. 2018 Oct 15;352:142-150. doi: 10.1016/j.bbr.2017.12.014. Epub 2017 Dec 10. Review.

PMID:
29237549
5.

Levodopa-induced abnormal involuntary movements correlate with altered permeability of the blood-brain-barrier in the basal ganglia.

Lerner RP, Francardo V, Fujita K, Bimpisidis Z, Jourdain VA, Tang CC, Dewey SL, Chaly T, Cenci MA, Eidelberg D.

Sci Rep. 2017 Nov 22;7(1):16005. doi: 10.1038/s41598-017-16228-1.

6.

Neuroprotection and neurorestoration as experimental therapeutics for Parkinson's disease.

Francardo V, Schmitz Y, Sulzer D, Cenci MA.

Exp Neurol. 2017 Dec;298(Pt B):137-147. doi: 10.1016/j.expneurol.2017.10.001. Epub 2017 Oct 5. Review.

PMID:
28988910
7.

Dramatic differences in susceptibility to l-DOPA-induced dyskinesia between mice that are aged before or after a nigrostriatal dopamine lesion.

Bez F, Francardo V, Cenci MA.

Neurobiol Dis. 2016 Oct;94:213-25. doi: 10.1016/j.nbd.2016.06.005. Epub 2016 Jun 14.

PMID:
27312773
8.

M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia.

Shen W, Plotkin JL, Francardo V, Ko WK, Xie Z, Li Q, Fieblinger T, Wess J, Neubig RR, Lindsley CW, Conn PJ, Greengard P, Bezard E, Cenci MA, Surmeier DJ.

Neuron. 2016 Jun 1;90(5):1139. doi: 10.1016/j.neuron.2016.05.017. No abstract available.

9.

Gene therapy blockade of dorsal striatal p11 improves motor function and dyskinesia in parkinsonian mice.

Marongiu R, Arango-Lievano M, Francardo V, Morgenstern P, Zhang X, Cenci MA, Svenningsson P, Greengard P, Kaplitt MG.

Proc Natl Acad Sci U S A. 2016 Feb 2;113(5):1423-8. doi: 10.1073/pnas.1524387113. Epub 2016 Jan 19.

10.

M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia.

Shen W, Plotkin JL, Francardo V, Ko WK, Xie Z, Li Q, Fieblinger T, Wess J, Neubig RR, Lindsley CW, Conn PJ, Greengard P, Bezard E, Cenci MA, Surmeier DJ.

Neuron. 2015 Nov 18;88(4):762-73. doi: 10.1016/j.neuron.2015.10.039. Erratum in: Neuron. 2016 Jun 1;90(5):1139.

11.

Increased CSF biomarkers of angiogenesis in Parkinson disease.

Janelidze S, Lindqvist D, Francardo V, Hall S, Zetterberg H, Blennow K, Adler CH, Beach TG, Serrano GE, van Westen D, Londos E, Cenci MA, Hansson O.

Neurology. 2015 Nov 24;85(21):1834-42. doi: 10.1212/WNL.0000000000002151. Epub 2015 Oct 28.

12.

Rodent models of impulsive-compulsive behaviors in Parkinson's disease: How far have we reached?

Cenci MA, Francardo V, O'Sullivan SS, Lindgren HS.

Neurobiol Dis. 2015 Oct;82:561-573. doi: 10.1016/j.nbd.2015.08.026. Epub 2015 Aug 30. Review.

PMID:
26325219
13.

Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease.

Bastide MF, Meissner WG, Picconi B, Fasano S, Fernagut PO, Feyder M, Francardo V, Alcacer C, Ding Y, Brambilla R, Fisone G, Jon Stoessl A, Bourdenx M, Engeln M, Navailles S, De Deurwaerdère P, Ko WK, Simola N, Morelli M, Groc L, Rodriguez MC, Gurevich EV, Quik M, Morari M, Mellone M, Gardoni F, Tronci E, Guehl D, Tison F, Crossman AR, Kang UJ, Steece-Collier K, Fox S, Carta M, Angela Cenci M, Bézard E.

Prog Neurobiol. 2015 Sep;132:96-168. doi: 10.1016/j.pneurobio.2015.07.002. Epub 2015 Jul 21. Review.

PMID:
26209473
14.

Sigma-1 receptor: a potential new target for Parkinson's disease?

Francardo V.

Neural Regen Res. 2014 Nov 1;9(21):1882-3. doi: 10.4103/1673-5374.145351. No abstract available.

15.

Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism.

Francardo V, Bez F, Wieloch T, Nissbrandt H, Ruscher K, Cenci MA.

Brain. 2014 Jul;137(Pt 7):1998-2014. doi: 10.1093/brain/awu107. Epub 2014 Apr 22.

PMID:
24755275
16.

Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia.

Heiman M, Heilbut A, Francardo V, Kulicke R, Fenster RJ, Kolaczyk ED, Mesirov JP, Surmeier DJ, Cenci MA, Greengard P.

Proc Natl Acad Sci U S A. 2014 Mar 25;111(12):4578-83. doi: 10.1073/pnas.1401819111. Epub 2014 Mar 5.

17.

Investigating the molecular mechanisms of L-DOPA-induced dyskinesia in the mouse.

Francardo V, Cenci MA.

Parkinsonism Relat Disord. 2014 Jan;20 Suppl 1:S20-2. doi: 10.1016/S1353-8020(13)70008-7. Review.

PMID:
24262181
18.

Animal models of L-DOPA-induced dyskinesia: an update on the current options.

Iderberg H, Francardo V, Pioli EY.

Neuroscience. 2012 Jun 1;211:13-27. doi: 10.1016/j.neuroscience.2012.03.023. Epub 2012 Mar 21. Review.

PMID:
22465440
19.

A model of GDNF gene therapy in mice with 6-Hydroxydopamine lesions: time course of Neurorestorative effects and ERK1/2 activation.

Lindgren N, Francardo V, Quintino L, Lundberg C, Cenci MA.

J Parkinsons Dis. 2012;2(4):333-48. doi: 10.3233/JPD-012146.

PMID:
23938263
20.

Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia.

Ohlin KE, Francardo V, Lindgren HS, Sillivan SE, O'Sullivan SS, Luksik AS, Vassoler FM, Lees AJ, Konradi C, Cenci MA.

Brain. 2011 Aug;134(Pt 8):2339-57. doi: 10.1093/brain/awr165. Epub 2011 Jul 19.

21.

Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.

Francardo V, Recchia A, Popovic N, Andersson D, Nissbrandt H, Cenci MA.

Neurobiol Dis. 2011 Jun;42(3):327-40. doi: 10.1016/j.nbd.2011.01.024. Epub 2011 Feb 19.

PMID:
21310234
22.

Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia.

Fasano S, Bezard E, D'Antoni A, Francardo V, Indrigo M, Qin L, Doveró S, Cerovic M, Cenci MA, Brambilla R.

Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21824-9. doi: 10.1073/pnas.1012071107. Epub 2010 Nov 29.

Supplemental Content

Loading ...
Support Center